The 2026 Nobel Prize in Physiology or Medicine went to Karl Deisseroth, Peter Hegemann and Georg Nagel for discovering light-gated ion channels and developing optogenetics, a method that switches individual nerve cells on or off with light. The Nobel Assembly at Karolinska Institutet announced the award on October 5. The three will share 12 million Swedish kronor, about $1.2 million.
Key Takeaways
- American Karl Deisseroth, 54, and Germans Peter Hegemann, 71, and Georg Nagel, 73, share the prize equally.
- Hegemann and Nagel discovered channelrhodopsin, a light-sensitive protein in the single-celled alga Chlamydomonas, in the early 2000s.
- In 2005, Deisseroth’s Stanford lab put the channelrhodopsin gene into rat neurons and showed that blue light could make them fire on command.
- Labs around the world now use optogenetics to map the brain circuits behind memory, emotion and behavior.
- Clinical trials are testing optogenetics to restore some vision in people blinded by retinitis pigmentosa.
- The physics, chemistry, literature and peace prizes are announced later this week, and economics follows on Monday, October 12.
A Discovery That Started With Algae Swimming Toward Light
The prize-winning work began with basic biology, not a plan to treat disease. Peter Hegemann wanted to know how Chlamydomonas, a tiny green alga, sensed light and swam toward it. Working at the Max Planck Institute for Biochemistry in Martinsried, Germany, he found that the alga’s “eye spot” contained a protein that turned blue light into an electrical signal.
Georg Nagel helped pin down how that protein worked. He inserted Chlamydomonas genes into frog eggs and found that the protein, later named channelrhodopsin, formed a channel that opened when light hit it. The team described channelrhodopsin-1 in 2002 and channelrhodopsin-2 in 2003. The second version became the key tool for neuroscience.
That discovery showed something new: a single protein could take in light and produce an electrical current. Any cell engineered to carry the protein would also respond to light.
Karl Deisseroth Turned the Protein Into a Switch for Neurons
Karl Deisseroth, a physician-scientist at Stanford University and a Howard Hughes Medical Institute investigator, saw what this could mean for brain research. In 2005, his group put the channelrhodopsin gene into rat nerve cells and showed that short pulses of blue light made the cells fire. The method was named optogenetics a year later. Deisseroth’s team then showed it could control nerve cells in the brains of living mice.
Before optogenetics, neuroscientists could see which brain areas were active during a behavior but had trouble proving which specific cells caused it. With optogenetics, researchers can switch selected neurons on or off and watch what happens, which makes it possible to test cause and effect directly.
The Nobel Committee noted that the idea goes back to Francis Crick, the 1962 laureate, who suggested that light might one day be used to control specific cells. The three 2026 laureates provided the tool that made it possible.
German Research and American Application
The prize also shows how science moves across borders. The German laureates identified the molecule through work at Max Planck institutes and German universities. The American laureate built it into a research method at Stanford. Today Hegemann is at Humboldt University of Berlin, Nagel at the University of Würzburg, and Deisseroth remains at Stanford.
For international research policy, the story is a reminder that curiosity-driven research on an obscure alga, which had no obvious practical use at the time, produced one of neuroscience’s main tools two decades later. Deisseroth is the 36th current or former Howard Hughes Medical Institute scientist to win a Nobel Prize.
Medical Applications Are Still Early
The laureates themselves were careful about what optogenetics can do for patients so far. Georg Nagel, who heard the news while relaxing outdoors in Italy, said he knew of only one patient who had benefited from optogenetics and thought it might be too early for a prize in medicine.
That patient took part in a vision-restoration study. According to the Nobel Committee, researchers inserted a channelrhodopsin-like protein into the retina of a person blinded by retinitis pigmentosa, a disease that destroys the eye’s rods and cones, and the person regained some vision. Several clinical trials of this approach are ongoing.
Most of optogenetics’ impact so far has been in understanding disease rather than treating it. The Nobel Committee said the method has helped researchers learn more about the brain circuits involved in depression, anxiety, schizophrenia, Alzheimer’s disease and Parkinson’s disease. Whether that knowledge leads to new therapies is still an open question.
The Laureates Reacted With Surprise
Karl Deisseroth had been working late on a research paper and had just gone to bed when the Nobel Committee called. Georg Nagel was on vacation. Optogenetics had been on many scientists’ shortlists for years, so the timing surprised the laureates more than it surprised the field.
The medicine prize opens Nobel week, which continues with physics, chemistry, literature and peace before the economics prize on October 12.
FAQs
Who Won the 2026 Nobel Prize in Physiology or Medicine?
Karl Deisseroth of Stanford University, Peter Hegemann of Humboldt University of Berlin and Georg Nagel of the University of Würzburg won the prize. They were honored for discoveries about light-gated ion channels and optogenetics.
What Is Optogenetics?
Optogenetics uses light-sensitive proteins to turn specific nerve cells on or off with light. It lets scientists test which cells control particular behaviors, memories and emotions.
What Is Channelrhodopsin?
Channelrhodopsin is a light-sensitive protein discovered in the alga Chlamydomonas. When light hits it, it opens a channel that produces an electrical signal, which makes it useful for controlling neurons.
How Much Is the 2026 Nobel Prize in Medicine Worth?
The prize is 12 million Swedish kronor, about $1.2 million. The three laureates share it equally.
Is Optogenetics Used to Treat Patients?
Not yet as a standard treatment. Clinical trials are testing it to restore some vision in people with retinitis pigmentosa, and one trial participant has regained partial sight.
